Research Article
Analysis of Clinical Manifestations and Prognostic Factors Affecting Osteosarcoma

Jianghua Wei, Zhizhong Liang, and Gang Xu

Department of Bone and Soft Tissue Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, China

Correspondence should be addressed to Gang Xu; 2016120417@jou.edu.cn

Received 21 April 2022; Revised 9 July 2022; Accepted 25 July 2022; Published 4 August 2022

Academic Editor: Zhongjie Shi

Copyright © 2022 Jianghua Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study is aimed at exploring the clinical manifestations and prognostic factors of osteosarcoma. Methods. The clinical data of patients with osteosarcoma who were treated in our hospital from January 2018 to March 2020 were selected for retrospective analysis. The general information of the patients, including age, gender, tumor diameter, tumor location, tumor type, surgical method, and Enneking stage, distant disease metastasis, KPS score, and the number of postoperative adjuvant chemotherapy, were grouped by prognosis for statistical analysis. The clinical characteristics, morbidity and mortality, and prognostic factors of patients were statistically analyzed.

Results. Among the 83 patients in this group, there were 52 males and 31 females, 59 tumors > 10 cm in diameter and 24 tumors < 10 cm in diameter, 16 tumors in the upper limbs and 67 tumors in the lower limbs, 25 tumors in osteoblastoma, 16 tumors in chondroblastoma, 42 tumors in fibroblastoma, 62 tumors in stage II, and 21 tumors in stage III of Enneking stage, 10 tumors in distant metastasis, and 10 tumors in distant metastasis. The death rate of this group was 19.28% (16/83). Multifactor regression analysis confirmed that the Enneking stage III, distant metastasis, KPS score < 70, and the number of postoperative adjuvant chemotherapy < 6 were important factors influencing the death of osteosarcoma (P < 0.05). Conclusion. Enneking stage III, distant metastasis, KPS score < 70, and the number of postoperative adjuvant chemotherapy < 6 are important influencing factors of osteosarcoma death. Clinical practice can take corresponding preventive and control measures according to the existence of these factors to ensure a good prognosis.

1. Introduction

Osteosarcoma is a type of malignant bone tumor with a high incidence of malignancy, accounting for 15% of the total incidence of bone tumors. It is highly malignant, has a complex pathogenesis and progression, and can develop at any age [1]. Osteosarcoma has a high mortality rate and a poor prognosis, posing a great threat to the quality of life and physical and mental health of patients [2]. Surgery is an important treatment for osteosarcoma and has been used in the past for high/superarticular amputation, but it is very likely to affect the quality of life due to disability and has a low 1-year survival rate [3]. With the maturation of adjuvant interventional techniques such as chemotherapy, limb preservation has been widely used, but there is still a certain risk of death after limb preservation [4]; therefore, it is important to clarify the clinical manifestations and prognostic factors of osteosarcoma patients. This study is aimed at exploring the clinical manifestations and prognostic factors of osteosarcoma.

2. Data and Methods

2.1. General Information. In this study, the clinical data of patients with osteosarcoma who were treated in our hospital from January 2016 to March 2020 were selected for retrospective analysis. The inclusion criteria for this study were as follows: (1) confirmed by pathology and imaging, (2) osteosarcoma of the extremities, and (3) complete clinical data. The exclusion criteria for this study are as follows: (1) patients with metastases at the time of consultation, (2) patients with a history of tumor boundary destruction treatment, (3) patients with other systemic malignant tumors, (4) patients with other serious diseases, such as heart disease or
diabetes, (5) those who died of other reasons during the study period, (6) those who are pregnant or breastfeeding, and (7) those who have diseases of the immune system and blood system.

2.2. Methodology. Patients were grouped according to their prognosis, and the general conditions of all patients were statistically analyzed, including age, gender, tumor diameter, tumor location, tumor type, surgical method, Enneking stage, distant metastasis of the lesion, KPS score, and number of postoperative adjuvant chemotherapy [5, 6]. Statistical analysis was performed by two specially trained physicians, and when the results of the two were inconsistent, a third physician performed reanalysis.

2.3. Observed Indicators. Here are the following examples of the observed indicators: statistical analysis of the clinical characteristics of the patients in this group, statistical analysis of the morbidity and mortality rate of the patients in this group, and statistical analysis of the factors influencing the prognosis of osteosarcoma.

2.4. Statistical Analysis. The data were analyzed by using SPSS 22.0 software (IBM Statistics, Chicago, USA), the count data were presented as case number using the χ² test, the measurement data were confirmed to have chi-squared and to be approximately normally distributed by the Bartlett chi-squared test and the Kolmogorov-Smirnov normality test and were described by the mean ± standard deviation (SD), and the factors influencing the prognosis of osteosarcoma were analyzed by logistic multiple. The factors influencing the prognosis of osteosarcoma were analyzed by logistic regression. P value less than 0.05 was considered as significant difference.

3. Results

3.1. Analysis of Clinical Characteristics of This Group of Patients. This retrospective analysis contained 83 patients. The tumor types were osteoblastoma in 25 cases, chondroblastoma in 16 cases, fibroblastoma in 42 cases, stage II in 62 cases, and stage III in 21 cases. There were 10 cases with distant metastases and 73 cases without metastases.

3.2. Analysis of the Morbidity and Mortality Rate of Patients in This Group. Of the 83 patients in this group, 16 died of disease and 67 survived, with a morbidity and mortality rate of 19.28% (16/83).

3.3. Univariate Analysis of Factors Influencing Prognosis of Osteosarcoma. As shown in Table 1, there was no statistically significant difference in the survival of patients with osteosarcoma with different ages, gender, tumor diameter, tumor location, tumor type, and surgical methods (P > 0.05), and there was a statistically significant difference in the survival of patients with osteosarcoma with different Enneking stage, distant metastasis of the lesion, KPS score, and number of postoperative adjuvant chemotherapy (P < 0.05).

3.4. Multifactorial Analysis of Factors Affecting Prognosis of Osteosarcoma. With osteosarcoma death as the dependent variable and Enneking stage, distant metastasis of the lesion,
Patients with osteosarcoma. The lower the KPS score, the worse the physical and functional status of patients, so resection not only predicted the number of primary lesions but also the number of metastatic lesions, the severity of the disease, and the number of postoperative adjuvant chemotherapy < 6 were significant influencing factors for osteosarcoma death (P < 0.05, Table 2).

4. Discussion

Osteosarcoma is a type of primary malignant tumor of bone that occurs in children and adolescents, with a high degree of malignancy and a high rate of disability and death [7, 8]. In recent years, with the improvement of disease treatment technology, the survival rate of osteosarcoma has improved, but the overall prognosis is still difficult to reach the expected clinical level [9, 10]. Therefore, the disease characteristics and prognostic factors should be clarified, so that corresponding interventions can be made to minimize the risk of death.

This study retrospectively analyzed the clinical data of patients with osteosarcoma in our hospital. Our results show that Enneking stage III, distant metastasis of the lesion, KPS score < 70, and number of postoperative adjuvant chemotherapy < 6 are important factors that affect the death of osteosarcoma. The above factors may affect the death of osteosarcoma. The prognosis of patients with osteosarcoma has a significant impact because the Enneking stage is significantly positively correlated with the number of primary lesions, disease severity, and onset speed of disease progression. The Enneking stage was significantly positively correlated with the malignancy of osteosarcoma lesions, the severity of the disease, and the rate of disease progression, and the stage of the disease not only predicted the number of primary lesions but also the number of potential metastatic lesions. The KPS score can reflect the physical and functional status of patients with osteosarcoma. The lower the KPS score, the poorer the physical function, and it is usually difficult to tolerate radiotherapy treatment, which will affect the frequency and dose of radiotherapy and chemotherapy. Such patients are usually difficult to complete standard radiotherapy treatment. The prognosis is poor. Surgery can remove primary osteosarcoma lesions, but distant metastases are difficult to remove, which is also the main factor for the recurrence of osteosarcoma after treatment. Distant proliferation and metastasis of lesion cells can cause the disease. Postoperative adjuvant chemotherapy for osteosarcoma can excise distal metastatic osteosarcoma lesions or clear the lesions under microscope, thereby prolonging the survival period [11–13]. Therefore, when treating osteosarcoma, effective nutritional support should be given to those who have factors that affect the good outcome of the disease, so as to improve their body condition, enhance their chemotherapy tolerance, and ensure complete and standardized adjuvant chemotherapy treatment after surgery, thus completely eliminating lesions and metastases, prolonging the survival cycle, and improving the prognosis [14, 15]. Another study confirmed that postoperative pathological fracture is also an important factor affecting the prognosis of osteosarcoma, mainly because the pathological feature of osteosarcoma is osteolytic bone damage, and the higher the malignancy and longer the disease duration, the higher the bone fragility and the higher the risk of pathological fracture; therefore, pathological fracture patients usually have higher disease stage, higher malignancy, and longer disease duration; so, the risk of good regression is more difficult [16, 17], which is consistent with the conclusion of this study. There is a certain consistency with the findings of this study, and the clinical practice can promote good disease regression through comprehensive interventions such as enhancing bone density and nutrition.

In summary, Enneking stage III, distant metastasis of the lesion, KPS score < 70, and number of postoperative adjuvant chemotherapy < 6 are important factors influencing the death of osteosarcoma, and the clinical practice can take corresponding preventive and control measures according to the presence of the above factors to ensure the prognostic effect of the disease.

Data Availability

The data was within our manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References


Table 2: Multifactorial analysis of factors influencing prognosis of osteosarcoma.

<table>
<thead>
<tr>
<th>Variables</th>
<th>β</th>
<th>S.E.</th>
<th>Wald χ²</th>
<th>P</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enneking staged as stage III</td>
<td>1.189</td>
<td>0.405</td>
<td>8.621</td>
<td>&lt;0.001</td>
<td>3.284</td>
<td>1.776–6.073</td>
</tr>
<tr>
<td>Distant metastasis of the lesion</td>
<td>1.340</td>
<td>0.461</td>
<td>8.451</td>
<td>&lt;0.001</td>
<td>3.820</td>
<td>2.044–7.138</td>
</tr>
<tr>
<td>KPS score &lt; 70 points</td>
<td>1.578</td>
<td>0.535</td>
<td>8.698</td>
<td>&lt;0.001</td>
<td>4.845</td>
<td>3.665–6.404</td>
</tr>
<tr>
<td>Number of postoperative adjuvant chemotherapy &lt; 6 times</td>
<td>1.698</td>
<td>0.601</td>
<td>7.984</td>
<td>&lt;0.001</td>
<td>3.464</td>
<td>4.098–7.286</td>
</tr>
</tbody>
</table>


